A citation-based method for searching scientific literature

Pablo Lapuerta, Brian Zambrowicz, Paul Strumph, Arthur Sands. Diab Vasc Dis Res 2015
Times Cited: 76







List of co-cited articles
739 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members.
Jian Chen, Sandy Williams, Samantha Ho, Howard Loraine, Deborah Hagan, Jean M Whaley, John N Feder. Diabetes Ther 2010
183
11

Use of Adjuvant Pharmacotherapy in Type 1 Diabetes: International Comparison of 49,996 Individuals in the Prospective Diabetes Follow-up and T1D Exchange Registries.
Sarah K Lyons, Julia M Hermann, Kellee M Miller, Sabine E Hofer, Nicole C Foster, Birgit M Rami-Merhar, Grazia Aleppo, Jochen Seufert, Linda A DiMeglio, Thomas Danne,[...]. Diabetes Care 2017
34
26

Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials.
Julio Rosenstock, Jan Marquard, Lori M Laffel, Dietmar Neubacher, Stefan Kaspers, David Z Cherney, Bernard Zinman, Jay S Skyler, Jyothis George, Nima Soleymanlou,[...]. Diabetes Care 2018
144
11

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
11

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
Deepak L Bhatt, Michael Szarek, P Gabriel Steg, Christopher P Cannon, Lawrence A Leiter, Darren K McGuire, Julia B Lewis, Matthew C Riddle, Adriaan A Voors, Marco Metra,[...]. N Engl J Med 2021
579
11


Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial.
Satish K Garg, Emily G Moser, Bruce W Bode, Leslie J Klaff, William R Hiatt, Christie Beatson, Janet K Snell-Bergeon. Endocr Pract 2013
74
10

SGLT inhibitors in management of diabetes.
Abd A Tahrani, Anthony H Barnett, Clifford J Bailey. Lancet Diabetes Endocrinol 2013
194
10

Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes.
David R Powell, Deon Doree, Sabrina Jeter-Jones, Zhi-Ming Ding, Brian Zambrowicz, Arthur Sands. Diabetes Metab Syndr Obes 2015
15
53

SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.
Silvio E Inzucchi, Bernard Zinman, Christoph Wanner, Roberto Ferrari, David Fitchett, Stefan Hantel, Rosa-Maria Espadero, Hans-Jürgen Woerle, Uli C Broedl, Odd Erik Johansen. Diab Vasc Dis Res 2015
262
10

Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
Yoshihito Ohtake, Tsutomu Sato, Takamitsu Kobayashi, Masahiro Nishimoto, Naoki Taka, Koji Takano, Keisuke Yamamoto, Masayuki Ohmori, Marina Yamaguchi, Kyoko Takami,[...]. J Med Chem 2012
96
10

Luseogliflozin: first global approval.
Anthony Markham, Shelley Elkinson. Drugs 2014
65
12

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.
William T Cefalu, Lawrence A Leiter, Kun-Ho Yoon, Pablo Arias, Leo Niskanen, John Xie, Dainius A Balis, William Canovatchel, Gary Meininger. Lancet 2013
530
10

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.
H J Lambers Heerspink, D de Zeeuw, L Wie, B Leslie, J List. Diabetes Obes Metab 2013
503
10


Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus.
Panai Song, Akira Onishi, Hermann Koepsell, Volker Vallon. Expert Opin Ther Targets 2016
94
10

Glycaemic control of Type 1 diabetes in clinical practice early in the 21st century: an international comparison.
J A McKnight, S H Wild, M J E Lamb, M N Cooper, T W Jones, E A Davis, S Hofer, M Fritsch, E Schober, J Svensson,[...]. Diabet Med 2015
212
10


Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
Deepak L Bhatt, Michael Szarek, Bertram Pitt, Christopher P Cannon, Lawrence A Leiter, Darren K McGuire, Julia B Lewis, Matthew C Riddle, Silvio E Inzucchi, Mikhail N Kosiborod,[...]. N Engl J Med 2021
329
10

Active sugar transport in health and disease.
E M Wright, B A Hirayama, D F Loo. J Intern Med 2007
418
9

Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects.
B Komoroski, N Vachharajani, D Boulton, D Kornhauser, M Geraldes, L Li, M Pfister. Clin Pharmacol Ther 2009
255
9

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
James F List, Vincent Woo, Enrique Morales, Weihua Tang, Fred T Fiedorek. Diabetes Care 2009
477
9

Novel L-xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
Nicole C Goodwin, Ross Mabon, Bryce A Harrison, Melanie K Shadoan, Zheng Y Almstead, Yiling Xie, Jason Healy, Lindsey M Buhring, Christopher M DaCosta, Jennifer Bardenhagen,[...]. J Med Chem 2009
46
15

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
Anthony H Barnett, Ambrish Mithal, Jenny Manassie, Russell Jones, Henning Rattunde, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
387
9

Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.
R Chilton, I Tikkanen, C P Cannon, S Crowe, H J Woerle, U C Broedl, O E Johansen. Diabetes Obes Metab 2015
302
9

Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis.
A Liakos, T Karagiannis, E Athanasiadou, M Sarigianni, M Mainou, K Papatheodorou, E Bekiari, A Tsapas. Diabetes Obes Metab 2014
145
9

Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level.
Kenji Katsuno, Yoshikazu Fujimori, Yukiko Takemura, Masahiro Hiratochi, Fumiaki Itoh, Yoshimitsu Komatsu, Hideki Fujikura, Masayuki Isaji. J Pharmacol Exp Ther 2007
205
9


Synthesis and biological evaluation of C-glucosides with azulene rings as selective SGLT2 inhibitors for the treatment of type 2 diabetes mellitus: discovery of YM543.
Kazuhiro Ikegai, Masakazu Imamura, Takayuki Suzuki, Keita Nakanishi, Takeshi Murakami, Eiji Kurosaki, Atsushi Noda, Yoshinori Kobayashi, Masayuki Yokota, Tomokazu Koide,[...]. Bioorg Med Chem 2013
31
22

Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.
Masakazu Imamura, Keita Nakanishi, Takayuki Suzuki, Kazuhiro Ikegai, Ryota Shiraki, Takashi Ogiyama, Takeshi Murakami, Eiji Kurosaki, Atsushi Noda, Yoshinori Kobayashi,[...]. Bioorg Med Chem 2012
77
9

Ipragliflozin: first global approval.
Raewyn M Poole, Rosselle T Dungo. Drugs 2014
93
9


Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition.
Giulia Ferrannini, Thomas Hach, Susanne Crowe, Arjun Sanghvi, Kevin D Hall, Ele Ferrannini. Diabetes Care 2015
205
9

Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program.
Ngozi Erondu, Mehul Desai, Kirk Ways, Gary Meininger. Diabetes Care 2015
212
9

Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.
J Bolinder, Ö Ljunggren, L Johansson, J Wilding, A M Langkilde, C D Sjöström, J Sugg, S Parikh. Diabetes Obes Metab 2014
314
9

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
9



The role of SGLT1 and GLUT2 in intestinal glucose transport and sensing.
Pia V Röder, Kerstin E Geillinger, Tamara S Zietek, Bernard Thorens, Hermann Koepsell, Hannelore Daniel. PLoS One 2014
230
9

Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes.
Satish K Garg, Paul Strumph. N Engl J Med 2018
15
46

Development of SGLT1 and SGLT2 inhibitors.
Timo Rieg, Volker Vallon. Diabetologia 2018
132
9

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
9

Glucose/galactose malabsorption caused by a defect in the Na+/glucose cotransporter.
E Turk, B Zabel, S Mundlos, J Dyer, E M Wright. Nature 1991
286
7

T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes.
A Oku, K Ueta, K Arakawa, T Ishihara, M Nawano, Y Kuronuma, M Matsumoto, A Saito, K Tsujihara, M Anai,[...]. Diabetes 1999
192
7

Expression of monosaccharide transporters in intestine of diabetic humans.
J Dyer, I S Wood, A Palejwala, A Ellis, S P Shirazi-Beechey. Am J Physiol Gastrointest Liver Physiol 2002
207
7

KGA-2727, a novel selective inhibitor of a high-affinity sodium glucose cotransporter (SGLT1), exhibits antidiabetic efficacy in rodent models.
Toshihide Shibazaki, Masaki Tomae, Yukiko Ishikawa-Takemura, Nobuhiko Fushimi, Fumiaki Itoh, Mitsuhiko Yamada, Masayuki Isaji. J Pharmacol Exp Ther 2012
58
10

Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension.
Ilkka Tikkanen, Kirsi Narko, Cordula Zeller, Alexandra Green, Afshin Salsali, Uli C Broedl, Hans J Woerle. Diabetes Care 2015
309
7

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.
Silvio E Inzucchi, Richard M Bergenstal, John B Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne L Peters, Apostolos Tsapas, Richard Wender, David R Matthews. Diabetes Care 2015
7

C-Glucosides with heteroaryl thiophene as novel sodium-dependent glucose cotransporter 2 inhibitors.
Yuichi Koga, Shigeki Sakamaki, Mitsuya Hongu, Eiji Kawanishi, Toshiaki Sakamoto, Yasuo Yamamoto, Hirotaka Kimata, Keiko Nakayama, Chiaki Kuriyama, Yasuaki Matsushita,[...]. Bioorg Med Chem 2013
18
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.